Aarkstore - TGF-Beta-1 Inhibitors -Pipeline Insights, 2014

1
TGF-Beta-1 Inhibitors -Pipeline Insights,
2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/76035/tgf-beta-1-inhibitors-pipeline-insights-20
  14

2
Summary

• DelveInsights,TGF-Beta-1 Inhibitors-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  mechanism of action (MOA). A key objective of the
  report is to establish the understanding for all
  the pipeline drugs that fall under TGF-Beta-1
  Inhibitors. This report provides information on
  the therapeutic development based on the
  TGF-Beta-1 Inhibitors dealing with mechanism of
  action, comparative analysis at various stages
  covering Filed, Phase III, Phase II, Phase I, IND
  filed, Preclinical, Discovery and unknown stages,
  therapeutics assessment by monotherapy and
  combination products and molecule type drug
  information. The report also covers the companies
  information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of TGF-Beta-1
  InhibitorsThe report provides pipeline products
  under drug profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the TGF-Beta-1 Inhibitors
  pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for TGF-Beta-1
  Inhibitors and also provide company profilingThe
  report also gives the information of dormant and
  discontinued pipeline projects Pipeline products
  coverage based on various stages of development
  ranging from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for TGF-Beta-1 InhibitorsIdentify
  the relationship between the drugs and use it for
  target finding, drug repurposing, and precision
  medicine.Devise corrective measures for pipeline
  projects by understanding TGF-Beta-1 Inhibitors
  pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  Decisions
• You can order full Report with TOC and for Sample
  page visit _at_
• http//www.aarkstore.com/pharmaceuticals-healthca
  re/76035/tgf-beta-1-inhibitors-pipeline-insights-2
  014

7
Table of Content

• TGF-Beta-1 Inhibitors OverviewTGF-Beta-1
  Inhibitors Disease AssociatedTGF-Beta-1
  Inhibitors Pipeline TherapeuticsTGF-Beta-1
  Inhibitors Therapeutics under Development by
  Companies TGF-Beta-1 Inhibitors Late Stage
  Products (Filed and Phase III)Comparative
  Analysis TGF-Beta-1 Inhibitors Mid Clinical
  Stage Products (Phase II)Comparative
  Analysis TGF-Beta-1 Inhibitors Early Clinical
  Stage Products (Phase I and IND
  Filed)Comparative Analysis TGF-Beta-1
  Inhibitors Discovery and Pre-Clinical Stage
  Products Comparative Analysis Drug Candidate
  Profiles

8
Table of Content

• TGF-Beta-1 Inhibitors Therapeutics
  Assessment Assessment by Monotherapy
  Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type TGF-Beta-1 Inhibitors Discontinued
  Products TGF-Beta-1 Inhibitors Dormant
  ProductsCompanies Involved in Therapeutics
  Development for TGF-Beta-1 Inhibitors Appendix M
  ethodology Contact Us Disclaimer

9
List of Tables

• Number of Products under Development for
  TGF-Beta-1 Inhibitors by Therapy Area,
  2014Number of Products under Development for
  TGF-Beta-1 Inhibitors, 2014Number of Products
  under Development by Companies Comparative
  Analysis by Late Clinical Stage Products (Filed
  and Phase III), 2014Comparative Analysis Mid
  Clinical Stage Products (Phase II),
  2014Comparative Analysis Early Clinical Stage
  Products (Phase I and IND Filed),
  2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  Profiles

10
List of Tables

• TGF-Beta-1 Inhibitors Assessment by Monotherapy
  Products TGF-Beta-1 Inhibitors Assessment by
  Combination Products TGF-Beta-1 Inhibitors
  Assessment by Route of Administration TGF-Beta-1
  Inhibitors Assessment by Stage and Route of
  Administration TGF-Beta-1 Inhibitors Assessment
  by Molecule Type TGF-Beta-1 Inhibitors
  Assessment by Stage and Molecule Type TGF-Beta-1
  Inhibitors Therapeutics Discontinued
  Products TGF-Beta-1 Inhibitors Therapeutics
  Dormant ProductsProducts under Development by
  Companies, 2014

11
List of Figures

• Number of Products under Development for
  TGF-Beta-1 Inhibitors by Therapy Area,
  2014Number of Products under Development for
  TGF-Beta-1 Inhibitors, 2014Late Clinical Stage
  Products (Filed and Phase III), 2014Mid Clinical
  Stage Products (Phase II), 2014Early Clinical
  Stage Products (Phase I and IND Filed),
  2014Discovery and Pre-Clinical Stage Products,
  2014TGF-Beta-1 Inhibitors Assessment by
  Monotherapy Products TGF-Beta-1 Inhibitors
  Assessment by Combination Products TGF-Beta-1
  Inhibitors Assessment by Route of
  Administration TGF-Beta-1 Inhibitors Assessment
  by Stage and Route of Administration TGF-Beta-1
  Inhibitors Assessment by Molecule
  Type TGF-Beta-1 Inhibitors Assessment by Stage
  and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• TGF-Beta-1 Inhibitors -Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,TGF-Beta-1 Inhibitors-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  mechanism of action (MOA).
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news